TABLE III.
Disease and treatment characteristics
| Characteristic | Patient group | ||
|---|---|---|---|
|
| |||
| Overall (n=42) | Intervention (n=21) | Control (n=21) | |
| Site [n (%)] | |||
| Nasopharynx | 10 (23.8) | 4 (19) | 6 (28.6) |
| Oropharynx | 26 (61.9) | 13 (61.9) | 13 (61.9) |
| Larynx | 3 (7.1) | 2 (9.5) | 1 (4.8) |
| Unknown primary | 3 (7.1) | 2 (9.5) | 1 (4.8) |
| Tumour stage [n (%)] | |||
| T0 | 3 (7.1) | 2 (9.5) | 1 (4.8) |
| T1 | 10 (23.8) | 5 (23.8) | 5 (23.8) |
| T2 | 14 (33.3) | 7 (33.3) | 7 (33.3) |
| T3 | 11 (26.2) | 5 (23.8) | 6 (28.6) |
| T4 | 2 (4.8) | 0 (0) | 2 (9.5) |
| T4a | 2 (4.8) | 2 (9.5) | 0 (0) |
| Lymph node status [n (%)] | |||
| N0 | 3 (7.1) | 1 (4.8) | 2 (9.5) |
| N1 | 3 (7.1) | 2 (9.5) | 1 (4.8) |
| N2 | 4 (9.5) | 0 (0) | 4 (19) |
| N2a | 3 (7.1) | 1 (4.8) | 2 (9.5) |
| N2b | 15 (35.7) | 8 (38.1) | 7 (33.3) |
| N2c | 10 (23.8) | 6 (28.6) | 4 (19) |
| N3 | 4 (9.5) | 3 (14.3) | 1 (4.8) |
| Stage [n (%)] | |||
| II | 2 (4.8) | 1 (4.8) | 1 (4.8) |
| III | 8 (19) | 4 (19) | 4 (19) |
| IVA | 28 (66.7) | 12 (57.1) | 16 (76.2) |
| IVB | 4 (9.5) | 4 (19) | 0 (0) |
| Squamous cell histology [n (%)] | 42 (100) | 21 (100) | 21 (100) |
| Radiation treatment | |||
| Mean treatments (n fractions) | 34.9±0.3 | 35±0.2 | 34.9±0.4 |
| Total dose (Gy) | 69.7 (1.7) | 69.9 (0.4) | 69.5 (2.3) |
| Chemotherapy | |||
| Mean total cisplatin dose (mg) | 409.3 ±114.5 | 380.3 ±118.1 | 438.3 ±105.6 |